poisar

Stocks · News reference

OKYO Pharma Says Chief Medical Officer, Flavio Mantelli, Purchases 20,000 Of Its Ordinary Shares On NASDAQ At $1.40 Per Share

Jul 22, 2026, 11:08 AMBenzinga Newsdesk

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OKYO
Source
benzinga
Observed
Jul 22, 2026, 11:08 AM
Checked
Jul 22, 2026, 11:08 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading